Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals Inc. (ARWR) is a clinical-stage biotechnology leader developing RNA interference (RNAi) therapies that target disease-causing genes. This page provides investors and industry professionals with verified updates on the company's progress in advancing treatments for genetic disorders through its proprietary TRIM™ delivery platform.
Access consolidated, factual reporting of Arrowhead's material developments including clinical trial milestones, regulatory submissions, research collaborations, and financial disclosures. Our news aggregation ensures efficient tracking of therapeutic advancements in hepatitis B, cardiovascular diseases, and rare genetic conditions.
All content undergoes strict verification to maintain compliance with financial reporting standards. For stakeholders monitoring RNAi innovation and precision medicine breakthroughs, this resource offers centralized access to essential updates without speculative commentary.
Bookmark this page for streamlined monitoring of Arrowhead's progress in developing targeted gene silencing therapies. Check regularly for authoritative reporting on pipeline developments and strategic initiatives shaping the future of RNA-based medicine.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022. Investors can access the live audio webcast on the Company's website. A replay will be available for 90 days.
Arrowhead develops innovative RNAi-based therapeutics targeting intractable diseases through gene silencing.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has approved inducement grants for 34 new employees on July 1, 2022. The grants comprise a total of 138,000 restricted stock units, with 70,000 units awarded to the new chief commercial officer, Tracie Oliver. These grants are outside the company's stockholder-approved equity incentive plans and will vest over four years. Arrowhead focuses on developing RNA interference-based therapies to treat severe diseases by silencing problematic genes.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing in two Phase 1/2a clinical trials for ARO-MUC5AC and ARO-RAGE, innovative RNA interference therapeutics targeting mucin production and inflammatory responses in lung diseases. ARO-MUC5AC-1001 and ARO-RAGE-1001 trials aim to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and asthma patients. CEO Chris Anzalone highlighted this as a pivotal milestone in the company's mission to tackle difficult-to-drug targets in respiratory conditions.
Takeda (TAK) and Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced promising results from the Phase 2 AROAAT-2002 study of fazirsiran for liver disease due to alpha-1 antitrypsin deficiency (AATD). Key findings include a 58% fibrosis regression in treated patients, an 83% median reduction in Z-AAT accumulation in the liver, and a 69% reduction in histologic globule burden. Fazirsiran aims to tackle AATD's liver manifestations, with plans for a Phase 3 study on the horizon. The collaboration has received Breakthrough Therapy and Orphan Drug designations from the FDA.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is set to participate in several key healthcare conferences in June 2022. Events include the Jefferies Healthcare Conference from June 8-10 and the Goldman Sachs 43rd Annual Global Healthcare Conference from June 13-16, both featuring presentations by Vincent Anzalone, Vice President Finance and Investor Relations.
Additionally, they will present at The International Liver Congress™ 2022, discussing significant studies related to chronic hepatitis B. Further details can be accessed through their Events and Presentations webpage.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is hosting a pulmonary R&D Day in New York City to unveil its pipeline of RNA interference therapeutics targeting pulmonary diseases. Key presentations include ARO-MUC5AC, ARO-RAGE, and ARO-MMP7, aimed at treating muco-obstructive and inflammatory conditions. ARO-RAGE shows over 90% mRNA reduction in preclinical studies, while ARO-MUC5AC promises significant silencing of pathogenic expression. ARO-MMP7 targets idiopathic pulmonary fibrosis. The event will enhance confidence in upcoming clinical trials.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported strong financial results for Q2 FY2022, demonstrating a revenue increase to $151.8 million, up from $32.8 million in Q2 FY2021. The company achieved a net income of $44.4 million, or $0.41 per diluted share, compared to a loss of $26.8 million in the previous year. Key developments include the initiation of several clinical studies for its investigational RNA interference therapeutics, which target various conditions, alongside the formation of a joint venture in Greater China and the groundbreaking of a new manufacturing facility.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has commenced construction on a new drug manufacturing facility in Verona, WI, expected to span about 160,000 square feet, alongside a 125,000 square foot laboratory and office space. The company has been awarded $16 million in tax increment financing from Verona and $2.5 million in refundable income tax credits from the Wisconsin Economic Development Corporation. Completion of the lab is anticipated by 2023, while the manufacturing facility is expected to finish in 2024, aiming to support the development of innovative RNAi-based therapies.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) appointed Victoria Vakiener as an independent director, effective May 2, 2022. Vakiener brings extensive experience, including leadership roles at Epizyme and Johnson & Johnson, aimed at guiding Arrowhead's growth in RNAi technology commercialization. Chairman Douglass Given praised her ability to help the company transition into a commercial stage. This strategic addition underscores Arrowhead's commitment to enhancing its leadership as it focuses on advancing its innovative gene-silencing therapies to tackle intractable diseases.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in several upcoming conferences in May 2022. Events include TIDES USA 2022 from May 9-12, where Michael Lawler will discuss scale-up manufacturing. At the American Thoracic Society Conference from May 13-18, David Kasahara will present on RNAi delivery platforms targeting lung inflammation. Arrowhead will also participate in the BofA Securities Healthcare Conference and the RBC Capital Markets Healthcare Conference on May 12 and 17, respectively, both featuring Christopher Anzalone. Further details are available on their website.